MBIO Archives - BioTuesdays

Developments

MindBio gets ethics okay for take-home LSD-microdosing trial in MDD

MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) received ethics approval for a world’s first Phase 2a take-home LSD-microdosing clinical trial in patients with major depressive disorder (MDD) in New Zealand. The...

May 23, 2023

Developments

MindBio Therapeutics lists on CSE

MindBio Therapeutics (CSE:MBIO) has listed its common shares on the Canadian Securities Exchange under the ticker symbol, MBIO. MindBio is the only company in the world to have clinical trials approved for LSD take-home...

May 5, 2023

Markets

BTIG starts coverage of six cell therapy and immuno-oncology companies at buy

BTIG initiated coverage on six companies with “buy” ratings that it believes are undervalued players in the cell therapy space, each developing some variation of autologous CAR-Ts, “off-the-shelf” allogeneic CAR-Ts...

May 17, 2021

Developments

Mustang Bio MB-107 gets FDA rare pediatric disease designation

The FDA granted Mustang Bio’s (NASDAQ:MBIO) MB-107 rare pediatric disease designation for the treatment of X-linked severe combined immunodeficiency. Patients with X-linked severe combined immunodeficiency produce...

August 17, 2020

Developments

Mustang Bio MB-107 gets EMA advanced therapy medicinal product classification

The European Medicines Agency granted Mustang Bio’s (NASDAQ:MBIO) MB-107 with advanced therapy medicinal product classification for the treatment of X-linked severe combined immunodeficiency. Patients with X-linked...

April 20, 2020

Markets

HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12. Analyst Joseph Pantginis writes that Mustang is developing multiple novel...

August 13, 2019

Developments

FDA clears Mustang Bio IND for CAR T cell therapy

Mustang Bio (NASDAQ:MBIO) reported that the FDA approved its IND application for MB-102 for the treatment of acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk...

August 6, 2019

Developments

Mustang Bio gets FDA orphan drug designation for malignant glioma

Mustang Bio (NASDAQ:MBIO) and development partner, Nationwide Children’s Hospital (NCH), received FDA orphan drug designation for MB-108 for the treatment of malignant glioma. Malignant glioma is a type of brain cancer...

May 17, 2019

Tag - MBIO

MindBio gets ethics okay for take-home LSD-microdosing trial in MDD

MindBio Therapeutics lists on CSE

BTIG starts coverage of six cell therapy and immuno-oncology companies at buy

Mustang Bio MB-107 gets FDA rare pediatric disease designation

Mustang Bio MB-107 gets EMA advanced therapy medicinal product classification

HCW starts Mustang Bio at buy; PT $7

FDA clears Mustang Bio IND for CAR T cell therapy

Mustang Bio gets FDA orphan drug designation for malignant glioma

General

More